MV LASV
Alternative Names: Lassa fever vaccine - Themis Bioscience; MV-LASVLatest Information Update: 28 Oct 2022
Price :
$50 *
At a glance
- Originator Themis Bioscience
- Class Attenuated vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Lassa fever
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for phase-I development in Lassa-fever(Prevention) in Belgium (IM, Injection)
- 15 Jan 2021 Themis Bioscience completes a phase I trial in Lassa fever (Prevention) in Belgium (NCT04055454)
- 19 Jun 2020 Themis Bioscience has been acquired by Merck & Co